Wilson I Gonsalves, Francis K Buadi, Sikander Ailawadhi, P Leif Bergsagel, Asher A Chanan Khan, David Dingli, Angela Dispenzieri, Rafael Fonseca, Susan R Hayman, Prashant Kapoor, Taxiarchis V Kourelis, Martha Q Lacy, Jeremy T Larsen, Eli Muchtar, Craig B Reeder, Taimur Sher, A Keith Stewart, Rahma Warsame, Ronald S Go, Robert A Kyle, Nelson Leung, Yi Lin, John A Lust, Stephen J Russell, Stephen R Zeldenrust, Amie L Fonder, Yi L Hwa, Miriam A Hobbs, Angela A Mayo, William J Hogan, S Vincent Rajkumar, Shaji K Kumar, Morie A Gertz, Vivek Roy
Over the last two decades, the utilization of various novel therapies in the upfront or salvage settings has continued to improve survival outcomes for patients with Multiple Myeloma (MM). Thus, the conventional role for hematopoietic stem cell transplantation (HSCT) in MM either in the form of an autologous stem cell transplant (ASCT) or an allogeneic stem cell transplant (Allo-SCT) warrants re-evaluation, given the aforementioned clinical advances. Here, we present a consensus statement of our multidisciplinary group of over 30 Mayo Clinic physicians with a special interest in the care of patients with MM and provide evidence-based recommendations on the use of HSCT in MM...
March 2019: Bone Marrow Transplantation